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Methemoglobinaemia is an infrequent haematological disorder that can result from congenital and 
acquired conditions. The congenital form is rare 
and not always compatible with life, but acquired 
methemoglobinaemia is more common and can 
result from a wide variety of environmental agents, 
including prescribed and recreational drugs. 
Oxygen therapy and intravenous methleyne blue is 
usually the first line treatment for this disorder. A 
high level of suspicion is necessary for the accurate 
and timely diagnosis of this condition, as any delay 
can be catastrophic. 
Case One
A 39-year-old male with no significant past medical 
history presented to the emergency department 
after collapsing following recreational ingestion of 
alkyl nitrates (‘poppers’). He denied using any other 
recreational, prescribed, or over-the-counter drugs. 
Upon presentation, the patient was fully awake 
and oriented, with a Glasgow Coma Score (GCS) 
of 15/15, and no significant abnormal findings on 
initial clinical examination. The electrocardiogram 
(ECG), chest radiograph, and initial blood 
investigations were within the normal stated local 
limits. Pulse oximetry revealed oxygen saturations 
of 85–88% whilst breathing room air. 
Arterial blood gas (ABG) analyses and oxygen 
saturations as measured on pulse oximetry 
are shown in Table 1. A diagnosis of acquired 
methemoglobinaemia was made and, as such, 
definitive treatment with high flow oxygen (15 
litres delivered via a non-rebreathing mask) and 
intravenous methylene blue (1.5 mg/kg infused 
over 10 minutes) was initiated. The measured 
ABG (including methaemoglobin [MetHb] levels) 
returned to within normal limits within 24 hours of 
his admission, as shown in Table 1. 
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بِيَلُة امليتهيموغلوبني املكتسبة
عادل اللواتي، نك مريج
امللخ�ص: بيَلُة امليتهيموغلوبني املكت�سبة حالة نادرة ن�سبيا، ولهذا كانت قليلة الورود يف املمار�سة الطبية احلادة. قد ينجم اال�ستباه يف 
اأَْك�ُسج النب�سي. ُندرج يف هذا  احلالة عندما يكون قيا�س �سغط االأك�سجني ال يتنا�سب مع ت�سبع االأك�سجني التي يتم اكت�سافها حني ِقيا�ُس التَّ
التقرير و�سفا حلالتني منف�سلتني من بيَلُة امليتهيموغلوبني الناجتة عن ا�ستعمال األكيل نرتيت الأغرا�س الرتفيه. راجع املري�سان يف فرتات 
خمتلفة اثنني من امل�ست�سفيات التعليمية املختلفة يف لندن، اململكة املتحدة. وقد اأدى الت�سابه بني هاتني احلالتني اإىل �رضورة رفع م�ستوى 
الوعي اجتاه هذه احلالة القاتلة، وارتباطها باالأدوية املتاحة على نطاق وا�سع لالأغرا�س الرتفيهية، الأنه اأمر �رضوري ل�سمان الت�سخي�س 
ال�سحيح ويف الوقت املنا�سب.
مفتاح الكلمات: بيلة امليتهيموجلوبني، ميثيلني اأزرق، تقرير حالة، اململكة املتحدة.
abstract: Acquired methemoglobinaemia is a relatively rare condition and, therefore infrequently encountered 
in acute medical practice. Suspicion of the condition may be triggered when the measured PaO2 is ‘out of keeping’ 
with the oxygen saturations that are discovered with pulse oximetry. We describe two separate cases of acquired 
methemoglobinaemia secondary to the recreational use of alkyl nitrites (’poppers’). The patients presented at 
separate times to two different teaching hospitals in London, UK. The similarity of these cases has led the authors 
to conclude that a raised awareness of this potentially fatal condition, and its association with a widely-available 
recreational drug, is necessary to ensure a correct and timely diagnosis.
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The patient was discharged after an uneventful 
48-hour inpatient stay, having received counselling 
regarding the potential dangers associated with the 
misuse of poppers. 
Case Two
A 40-year-old male with a significant smoking 
history was found collapsed after ingesting two 
beers and a bottle of poppers within a period of 
30 minutes. The patient voluntarily provided a full 
glass bottle similar to the one ingested [Figure 1].
On arrival in the emergency department the 
patient was fully orientated, with a GCS of 15/15. 
On clinical examination he was unkempt with tar-
stained fingers. The patient was also noted to be 
centrally cyanosed with a mild bilateral expiratory 
wheeze. The rest of the initial clinical examination 
was largely unremarkable. An ECG revealed a sinus 
tachycardia with left axis deviation.  ABG analyses 
and oxygen saturations as measured on pulse 
oximetry are shown in Table 2.
Acquired methemoglobinaemia with possible 
previously unidentified chronic obstructive 
pulmonary disease was diagnosed; therefore, the 
patient was started on monitored high flow oxygen 
therapy with serial clinical assessments and ABGs, 
as well as intravenous methylene blue. The patient 
was discharged after education about the potential 
effects of abusing poppers, smoking cessation 
advice, and inhaled bronchodilator therapy for his 
probable chronic obstructive pulmonary disease. 
He was also given follow-up appointments with 
the chest clinic for further evaluation of his chest 
condition, but he did not attend.
Discussion
Methemoglobinaemia is a disorder in which 
the haemoglobin (Hb) molecule is altered to 
prevent efficient carriage of oxygen, essentially 
shifting the oxygen dissociation curve to the left, 
leading to a functional anaemia. A variety of 
aetiologies including genetic, dietary, idiopathic, 
and toxicological have been implicated.1 Acquired 
methemoglobinaemia is much more common than 
the hereditary form, occurring when an exogenous 
substance oxidises Hb to methaemoglobin 
(MetHb) at rates of 100 to 1000 times greater than it 
can be reduced back to its original form [Figure 2].2 
Congenital methemoglobinaemia can occur from 
a cytochrome b5 reductase deficiency or from a 
structural Hb defect, collectively called HbM. There 
Table 1: Case 1 arterial blood gas (ABG) results and measured oxygen saturation (SaO2) (on pulse oximetry)
Normal range Admission 24 hours after admission
Inspired oxygen (FiO 2) Room air (0.21) Room air (0.21) Room air (0.21)
SaO2 >96% 85–88% 98%
PaO2 10–13 kPa 8.5 kPa 12.4
PaCO2 5.4–6.8 kPa 5.7 kPa 5.8 kPa
MetHb % <1% (non-smokers) 23.5%  0.7%
Legend: FiO2 = fraction of inspired oxygen; SaO2 = oxygen saturation; PaO2 = partial pressure of oxygen in blood; PaCO2 = partial pressure of carbon 
dioxide in blood; MetHb = methaemoglobin; kPa = kilopascal.
 
Figure 1: Bottle of alkyl nitrite provided by Patient 2
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are two types of congenital methaemogloninaemia. 
In type 1, the enzyme deficiency is confined to 
the red blood cells, whereas in type 2 a range 
of cells, including brain cells, is affected. Type 2 
usually results in mental retardation, neurological 
abnormalities, or death in childhood. Lifelong use 
of agents having the same effect as the deficient 
reducing enzyme, such as ascorbic acid (vitamin 
C) and/or riboflavin (vitamin B2) can be used to 
try to alleviate some of the clinical features of the 
condition, especially in type 1. HbM results from 
a single amino acid substitution in either alpha or 
beta polypeptide chains at the region where the 
iron-containing heme portion is attached. This 
results in a failure to convert MetHb to Hb.3
Normally, there is a continuous conversion 
of Hb to MetHb, and vice versa. The reduction 
of MetHb to Hb happens through two different 
pathways. The nicotinamide dinucleotide (NADH)-
dependent cytochrome b5-methaemoglobin 
reductase pathways account for 99% of MetHb 
reduction to Hb. The other mechanism depends 
on utilising nicotinamide-adenine dinucleotide 
phosphate hydrogenase (NADPH) generated by 
glucose-6-phosphate dehydrogenase (G6PD) in the 
hexose monophosphate pathway. This mechanism 
is physiologically inactive and needs extrinsic 
agents, like methylene blue, to activate it. Whereas 
the former mechanism is the main physiologically 
active reducing mechanism, the later pathways are 
highly important when the physiologically active 
mechanism is overwhelmed and the therapeutic 
correction of MetHb is attempted via methylene 
blue.3  
Poppers are potent oxidisers of oxyhaemoglobin 
(converting Fe2+ to Fe3+) resulting in the formation 
of MetHb, and are volatile liquids that are 
sometimes abused by both sexes for euphorigenic 
rushes and altered states of consciousness. The 
name ‘poppers’ may have been derived from the 
sound caused by breaking open the glass vials 
which were originally used to store the volatile 
contents.4 Methemoglobinaemia has been reported 
to develop after the ingestion of as little as 10 ml 
of alkyl nitrite.5 Factors that may predispose to 
pharmacologically-induced methemoglobinaemia 
include the use of large quantities of the offending 
agent, any discontinuation of the body’s normal 
mucosal barriers, and the concomitant use of other 
drugs known to cause methaemoglobinaemia, such 
as acetaminophen (paracetamol), primaquine, 
or cocaine.6 In addition, dapsone has been 
implicated in almost 50% of cases of acquired 
methaemoglobinaemia, which is clinically 
important as, due to its relatively long half-life, 
cimetidine may be required to try to block its 
Table 2: Case 2 arterial blood gas (ABG) results and measured oxygen saturation (SaO2) (on pulse oximetry)
Normal range Admission 24 hours after admission
Inspired oxygen (FiO2) Room air (0.21) Non-rebreathe reservoir 
mask at 15L/min O2 (~ 0.90)?
Room air (0.21)
SaO2 >96% 90% 96%
PaO2 10–13 kPa 8.3 kPa 8.3 kPa
PaCO2 5.4–6.8kPa 6.2 kPa 6.1 kPa
MetHb % <1% (non-smokers) 46.0% 0.5%
Legend: FiO2 = fraction of inspired oxygen; SaO2 = oxygen saturation; PaO2 = partial pressure of oxygen in blood; PaCO2 = partial pressure of carbon 
dioxide in blood; MetHb = methaemoglobin; kPa = kilopascal.
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Figure 2: The role of methylene blue in the treatment of 
methaemoglobinemia
Legend: G6P = glucose 6 phosphate; G-6-PD = glucose-
6-phosphate dehydrogenase; R5P = ribose-5-phosphate; 
NADP = nicotine adenine dinucleotide phosphate; NADPH 
= nicotine adenine dinucleotide phosphate hydrogenase; 
MetHb = methaemaglobin; Hb = haemoglobin
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metabolism via hepatic microsomal cytochrome 
P450 (CYP450).7 Topical local anaesthetic 
agents  (e.g. lidoncaine or benozocaine) for 
procedures such as bronchoscopy, laryngoscopy, 
or upper gastroduodenoscopy can also result 
in acquired methaemoglobinaemia.2 Another 
risk factor for developing pharmacologically-
induced methemoglobinaemia is the presence 
of concomitant illnesses, including cardiac and 
respiratory diseases.8
This condition should be suspected if cyanosis 
develops after suspected exposure to potent 
oxidizing agents, or if chocolate brown arterial 
blood does not turn red on exposure to air.1 Some 
of the more common non-specific clinical features 
are listed in Table 3.6 However, clinical presentation 
may vary greatly and definitive treatment with 
methylene blue might not always be needed 
depending on the clinical condition.
Pulse oximetry is a useful tool to diagnose 
suspected methaemoglobinaemia. It basically works 
by emitting lights at two different wavelengths (660 
nm in the red spectrum wavelength and 940 nm in the 
infrared spectrum wavelength). These wavelengths 
are absorbed differently by deoxyhaemoglobin 
and oxyhaemoglobin (i.e. deoxyhaemoglobin 
absorbs more light at 660 nm wavelengths and 
oxyhaemoglobin absorbs more light at 940 nm 
wavelengths). By calculating the differences, the 
microprocessor in the pulse oximeter can measure 
the SaO2 (sometimes referred as SpO2 when 
measured by a pulse oximeter). Whereas MetHb 
absorbs more light than either oxyhaemoglobin 
and deoxyhaemoglobin at 940 nm wavelength, its 
absorption is similar to that of deoxyhaemoglobin 
at 660 nm wavelengths resulting in falsely low 
SaO2 due to an incorrectly high deoxyhaemoglobin 
perception by the pulse oximeter. However, newer 
pulse oximeters are able to omit light at 8 different 
wavelengths making it possible to measure MetHb 
and carboxyhaemoglobin as well.9
The diagnosis of methemoglobinaemia can be 
confirmed with an ABG sample that demonstrates 
a discrepancy between arterial oxyhaemoglobin 
saturation (SaO2) and measured arterial oxygen 
partial pressure (PaO2).
6 A high saturation gap should 
also lead to the suspicion of methaemoglobinaemia. 
The gap is defined as the difference between oxygen 
saturation measured by the pulse oximeter and that 
calculated by ABG. This gap is usually >5 in cases of 
methaemoglobinaemia.
10
Methylene blue can be an effective treatment 
for acquired methemoglobinaemia [Figure 2] 
and should be administered at a dose of 1–2 mg/
kg intravenously over 3–10 minutes. An obvious 
clinical improvement should be evident within one 
hour, but if cyanosis persists, a second dose may 
be considered.8 Higher doses of methylene blue 
(>7 mg/kg) may cause haemolysis and persistent 
cyanosis, as the agent can paradoxically oxidise 
haemoglobin to MetHb, as opposed to acting 
as a reducing agent at lower doses.5 Relapsing 
methemoglobinaemia has also been described in 
the literature with a delayed, biphasic rise in the 
level of MetHb. This may be due to a secondary 
paradoxical cyclical formation of MetHb by the 
offending agent (e.g. dapsone or methylene blue). 
CYP450 inhibitors (e.g. cimetidine) and exchange 
transfusion might be needed to treat these patients.8 
Also, individuals with G6PD deficiency may not 
produce sufficient NADPH to reduce methylene 
blue to leukomethylene blue, potentially rendering 
the therapy ineffective.6 Furthermore, methylene 
blue might induce haemolysis in G6PD-deficient 
patients. Alternative treatments with cimetidine, 
ascorbic acid, and possibly exchange transfusions 
,should be considered in patients with a G6PD, 
deficiency. N-acetylcysteine is also under study as 
a possible treatment for this category of patients.8 
Conclusion
We report a fatal medical condition which 
may result from the abuse of a widely-available 
recreational drug. Physicians in acute medical 
specialities should have a raised clinical suspicion 





Possible clinical features may 
include
<10 Often asymptomatic
10–20 Cyanosis, skin discolouration
20–30 Anxiety, light-headedness, headaches, 
tachycardia
30–50 Fatigue, confusion, dizziness, 
tachypnoea
50–70 Coma, seizures, acidosis, arrhythmias
>70 Death
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for this condition when there is a possible history 
of drug misuse and a significant discrepancy 
between the clinical picture and measured SaO2 
and PaO2 levels.  This raised level of awareness can 
ensure acquired methaemoglobinaemia’s accurate 
diagnosis and timely treatment. Both of our patients 
were discharged safely after timely diagnosis and 
management of a potentially life-threatening 
condition.
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